No Spotlight Needed

Perfect Chemistry: The Untold Story Behind the Hepatitis C Cure

What does a career look like when one chapter ends with an $11 billion acquisition, the next involves FBI visits and death threats, and the third ends with a devastating phase 3 failure that nobody saw coming?Dr. Michelle Berrey has lived all three. Over 15 years as a chief medical officer and CEO at Pharmasset, Chimerix, and Intercept Pharmaceuticals, she helped develop a cure for hepatitis C, navigated a national social media firestorm over a dying child, led a company through the Ebola outbreak, and faced a phase 3 failure that dropped the stock 90% overnight.In this conversation, she talks through every chapter with rare honesty, including what it takes to build a career-long relationship with the FDA, how she became CEO in 48 hours without asking for the job, and why the most important thing she ever learned was not to define yourself by your most recent result.Let's connect:LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneededTimestamps:0:00 - Teaser: death threats, the FBI, an $11B deal, and a 90% stock drop0:39 - Introduction: Dr. Michelle Berrey and her three biotech chapters2:26 - Three very different chapters: what have you learned?3:08 - Why Big Pharma drove her nuts and biotech set her free4:04 - Fail fast and focus: the operating philosophy that defined her career5:37 - Training during the HIV crisis at University of Washington6:12 - Standing outside bathhouses to understand transmission7:03 - Running her first clinical trials and learning to pay attention to outliers7:47 - Moving to GSK and using it like a university10:01 - Raising two kids as a single mom while building a career at Glaxo11:37 - The decision to leave Big Pharma for something more entrepreneurial12:43 - Joining Pharmasset as CMO: no committees, never looked back13:27 - The Hepatitis B phase three and the safety signal from Korea15:05 - Patient safety above everything: pivoting to Hep C16:44 - From the very first three patients, the viral load just kept dropping17:39 - The interferon question and why they went to New Zealand20:58 - Gilead approaches with an $11 billion offer at a 90% premium21:28 - Did you want to sell? "I didn't. It was my baby."22:23 - "It warms my heart every time I meet someone whose life was changed"22:36 - What made Pharmasset almost perfect: the chemistry and the prodrug23:41 - A fairytale ending on two fronts: the acquisition and a love story29:41 - The Josh Hardy story: a sick child and 80,000 tweets31:17 - "We had the FBI come in. We were getting death threats. The drug worked."32:02 - Named CEO in 48 hours: a field promotion she never asked for33:43 - The team that made the CEO role work35:49 - Six months later: Ebola and 2am calls with the FDA37:22 - A career-long relationship with the FDA built on trust and urgency39:09 - The SUPPRESS trial: December 15, 2015. Did not hit statistical significance.39:37 - Worse outcomes in the drug arm. "What does statistics matter when you're talking about lives."40:03 - Weeks of around the clock analysis: a protocol issue, not the drug40:36 - Stock falls 90%. A third of employees let go.42:12 - "The drug is not you"43:05 - Joining Intercept: a second FDA rejection already on the books44:16 - The complexity of liver biopsy endpoints compared to viral load45:42 - The advisory committee: "The odds were not in our favor"46:34 - Intercept sold to Alfasigma. Michelle steps away.47:46 - Advice to biotech teams: believe in your drug, stress test it, find the outliers50:19 - Is she done? "Richard thinks it's a sabbatical"50:54 - Mentoring young women in science51:46 - Closing reflections: when one door closes, another opportunity finds you

What $12 Billion in Biotech Exits Taught This CEO About Relationships, Risk, and Near-Death

What does it actually take to build a biotech from nothing... no IP, no programs, no money — into a company acquired by Eli Lilly for over $3 billion? In this episode of No Spotlight Needed, host Sheetal sits down with Praveen Tipirneni — engineer, physician, and military-trained biotech CEO who built Morphic Therapeutic over nine years, nearly died from an out-of-hospital cardiac arrest midway through, and still came back to close one of biotech's biggest deals of 2024. Now he's doing it again with Caldera Therapeutics. What we cover: - Why he sold before Phase 2B data — and the real math behind that call - Walking into his second board meeting ready to blow up the portfolio and get fired - Why people invest in people, not science — and the relationships that built every round - His no-PowerPoint writing culture (yes, before Bezos) - Why slowing down was always his instinct — and why it worked - The Friday the stock dropped 30% and the cardiac arrest that followed - His honest skepticism about AI in drug discovery - What drew him back to build Caldera Let’s connect: LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/ Connect with Praveen: https://www.linkedin.com/in/praveen-tipirneni-42a1a5/ Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 - Teaser: almost dying, relationships, and the stock drop Friday 0:40 - Intro: Praveen Tipirneni and the $3B Lilly acquisition 2:13 - Why sell Morphic before Phase 2B data? 3:06 - IBD isn't a disease a small company can commercialize 3:58 - The Olympics ad break analogy 5:41 - Not wanting to be CEO at 45 6:46 - The mentor who said "this is your window"8:26 - First six months at Morphic: sensing something was wrong 9:24 - "I don't just dislike our portfolio — I hate it" 10:47 - Starting from scratch: no IP, no programs, no money 13:13 - Why raising capital is all about relationships 14:26 - "Any biotech is a leap of faith. People invest in people." 15:02 - The Nils story: said no at Series A, led Series B 15:40 - Rajiv at Fidelity and how that relationship made the IPO 16:19 - The mistake: only calling investors when you're raising 17:13 - Morphic's use of Schrödinger and computational chemistry 19:39 - Why Praveen is an AI skeptic in drug discovery 21:50 - Building Morphic's culture: serious, deliberate, written 23:03 - The no-PowerPoint philosophy — before Bezos 25:28 - Tech vs. biotech: why "move fast" doesn't work here 28:22 - Being a conservative CEO — raising less than he could 29:02 - Letting people own their domains: the CFO story 33:25 - The cardiac arrest: stock drop, investor calls, and then nothing 35:30 - Two more arrests by Tuesday. Doctors said he wouldn't survive. 37:20 - "I should have died that day. Every day is not guaranteed." 38:47 - Why hiring great people meant the company ran without him 40:07 - The "break" that didn't last — and what pulled him back in 41:46 - Why he hired no one he knew for the first 2-3 years 43:21 - Cubist: joining a company at negative enterprise value 45:40 - What failures can you point to? 47:58 - CEO vs. Chairman: why they should always be separate 49:04 - Advice to founders: "It's never about the data" 50:46 - Life at Caldera: team-building, wearing every hat 53:18 - IPO as competitive moat and branding event 54:30 - Is biotech a race? What China has changed 54:48 - Free time: racing up mountains and everyone telling him to act his age 55:36 - Closing reflections

Former CEO Explains How to Build a Forever Company With Culture That STICKS!

Welcome to Season 2 of No Spotlight Needed! Episode 1 features Bruce Cozadd, former CEO of Jazz Pharmaceuticals. Bruce walks through the real moments behind building Jazz into a durable business, including what happened during the 2008 crash, how he thought about culture as the company scaled, why “bet the company” decisions need to be named out loud, and what it looks like to step away after a 20 plus year run without leaving a shadow behind. If you care about leadership, team building, and making hard calls with clarity, this one is a masterclass. What you’ll hear in this episode - What crisis leadership actually requires when people are scared - The “plan B, plan C, plan D” mindset that helped Jazz survive - A culture system that gives real signal, not lip service - When founders stay involved and when it hurts the new CEO - How to run succession without creating chaos Let’s connect:LinkedIn: https://www.linkedin.com/in/sheetal-mehta-prasad/ Our Website: https://www.nospotlightneeded.com/Subscribe to the Channel: https://www.youtube.com/@NoSpotlightNeeded/subscribe Timestamps: 0:00 Intro: why Jazz is “quietly different” 01:45 Building Jazz to create value without selling 04:49 Culture: defining it and making it measurable 06:06 Breakfast with Bruce: using new hires to gauge culture 08:02 Culture signals that actually matter (not slogans) 11:44 Founder staying involved: when it helps vs hurts 14:03 The danger of the old CEO “looking over your shoulder” 22:53 Going public: pros, cons, and ignoring the ticker 26:15 The 2008 to 2009 moment that almost ended Jazz 29:05 “Bet the company” decisions: name it out loud 30:14 Survival mode: cutting burn and reducing headcount 31:30 Mission and leadership: clarity, integrity, trust 41:09 Diversifying beyond one product: the long game 43:46 Measuring culture: surveys plus real employee comments 50:38 GW acquisition: criticism, conviction, and why it mattered 52:58 Retirement: how succession should work (without chaos)

The $20M to $400M Scaling Blueprint | Dorothy Gemmell Interview

In this Episode of No Spotlight Needed, Sheetal sits down with Dorothy Gemmell, a five time Chief Commercial Officer who helped scale multiple high growth healthcare businesses. No Spotlight Needed Website: https://www.nospotlightneeded.com/ Dorothy shares how she went from studying biochemistry at McGill University to pharmaceutical sales, then into leadership at 25, and eventually into the early internet era where she joined Medscape/WebMD as an early employee and helped scale revenue from about $20M to $400M+. You will hear her practical framework for hiring in fast growth environments, how to assess leaders in your first 90 days, when to remove toxic high performers, and why some of the best operators intentionally choose to stay in the number two seat. What you will learn: • Why early hires must include future leaders • The traits Dorothy screens for when hiring sales and commercial talent • A clear 90 day assessment process for leadership teams • Why toxicity has to go even if the person produces revenue • How Dorothy thinks about CEO strength vs CCO strength • The difference between VC, PE, and public company operating rhythms • How to preserve culture as headcount scales • Dorothy’s take on AI in healthcare and where it is already working Timestamps: 00:00 Dorothy introduced and leadership in high growth companies 00:29 When you know someone is the wrong person on the team 00:54 Why this conversation mattered to Sheetal 01:18 Dorothy’s early career and scaling experience preview 02:38 From pre med to business and pharma sales 03:15 Career day that changed her path 04:05 Why big company sales training matters 05:05 Why startups struggle to train people well 05:51 Becoming a district manager at 25 leading older reps 07:15 Leadership fundamentals and learning accountability 08:34 Why staying at a big company built her foundation 09:44 Lateral moves into marketing and international experience 10:58 Seeing the internet reshape healthcare and taking the leap 11:03 Why WebMD and Medscape felt like the future 12:08 Speeding up healthcare data and decisions via the internet 13:29 Joining Medscape early and loving the startup pace 15:06 Dot com volatility and leading through uncertainty 16:22 The balance between testing and burning cash 18:05 A blunt truth about job security in downturns 19:44 Hiring traits that scale teams in fast growth 21:12 Grit as a requirement in sales and startups 21:37 The 50 percent rule: hire people who can lead others 23:24 Numbers and accountability in commercial talent 24:39 Why she left WebMD and the noncompete lesson 26:19 CEOs do not need to know every job 27:27 The 90 day plan: change thoughtfully and fast 28:19 How Dorothy assesses leaders and teams 29:54 Toxicity has to go even when they are top performers 32:03 Set expectations early to reduce turmoil 33:24 The CEO traits that create loyalty and mission focus 36:11 Strategic discipline and avoiding the goat rodeo 36:53 Why Dorothy chooses to be number two 38:09 The personal cost of being CEO in growth companies 39:21 Work life balance: no guilt and being present 42:15 VC vs PE vs public: sprint marathon treadmill 44:14 Operating differences and resources by company type 46:16 Why she chose several smaller growth stints 48:05 Preserving culture as the company scales 50:09 C suite shifts: revenue plus margins and ops 51:14 What makes a strong executive team 52:29 Why offsites and relationship building matter 53:09 AI and the next chapter of healthcare 55:19 What she is most proud of: people she helped grow

Building a $14B Lab Business: David King on CEO Development, Decisions & Culture at Scale

Most people know LabCorp for routine blood work. But under CEO Dave King, the company expanded far beyond basic diagnostics, scaling from about $4B to $14B in revenue while navigating relentless pricing pressure, major acquisitions, and a rapidly changing healthcare landscape. In this conversation, Dave breaks down what it really takes to scale through M&A, why some deals worked and others missed expectations, and how to lead when decisions draw criticism. He also talks about Theranos, why he stayed quiet publicly, and how the science ultimately caught up. Finally, he shares how LabCorp built a unified, patient first culture across roles ranging from PhDs to couriers and phlebotomists, and why the team’s Covid response became one of his proudest moments. What you’ll hear in this episode: -The economics of the lab business and why volume matters -How Dave went from prosecutor and partner to LabCorp general counsel and then CEO -Building real compliance culture after a corporate integrity agreement -The biggest shift when you become CEO and why it takes time to learn the job -The “lazy with the numbers” moment and how it reshaped his leadership -LabCorp’s M&A strategy, including Genzyme Genetics and the Covance deal -Theranos behind the scenes and why LabCorp avoided taking the bait publicly -Navigating PAMA reimbursement cuts in a high fixed cost model-Succession, stepping away gracefully, and not becoming the “court of appeals” -How to build culture across a massive, diverse workforce -Why LabCorp’s Covid response is the moment he’s most proud of Timestamps: 00:00:00 LabCorp’s transformation and Dave King intro 00:01:10 The scale story: CEO tenure, growth, and deal reality 00:02:06 Early life: DC, Illinois, Berkeley 00:03:10 Princeton, public affairs, Near Eastern studies 00:03:32 Teaching high school and why he chose law 00:04:40 Traditional legal career: clerk, prosecutor, big firm 00:05:53 Meeting LabCorp through investigations 00:06:31 Why he moved in house and what changed personally 00:08:15 Compliance culture shift and staffing legal and compliance 00:09:23 Becoming CEO later in life and why that helped 00:11:31 The real CEO job versus ops leadership 00:13:09 “You’re lazy with the numbers” and the habit that fixed it 00:15:54 Strategy pivot: pricing pressure and broadening the revenue base 00:18:17 Genzyme Genetics and building leadership in genetics 00:20:23 Integration philosophy: one LabCorp culture 00:22:42 Deals you do not do and what he regrets not bolstering 00:24:52 Theranos: investor distraction, science reality, and why he stayed quiet 00:30:50 The Covance deal: why it mattered and the precision medicine thesis 00:33:10 Why Covance under delivered and what he learned 00:35:13 Leadership means decisions plus criticism 00:36:03 PAMA cuts: what happens in high fixed cost economics 00:39:06 Retirement planning and timing 00:40:35 Succession and stepping away gracefully 00:43:29 Not the court of appeals: how to support the new CEO 00:44:35 Culture across roles: scientists, couriers, phlebotomists 00:48:09 Senior team stability and deliberate hiring 00:49:47 Proud moments: the Covid response and the team’s intensity 00:52:19 Closing thoughts